title: Comparison of the utility and applicability of the Sokal, Hasford, and EUTOS scores in a population of Chinese patients with chronic-phase chronic myeloid leukemia undergoing imatinib therapy.
abstract: BACKGROUND
  Tyrosine kinase inhibitors are increasingly used to treat chronic myeloid leukemia (CML), but loss of complete cytogenetic response (CCyR) indicates treatment failure.
  
  
  OBJECTIVE
  To compare the efficacy of Sokal, European Treatment Outcome Study (EUTOS), and Hasford prognostic scores with 3-month and 12-month CCyR, event-free survival (EFS) and progression-free survival (PFS) in patients with chronic-phase CML (CP-CML) undergoing imatinib therapy.
  
  
  METHODS
  We retrospectively analyzed the outcome of 210 patients with CP-CML treated at the First Affiliated Hospital of Anhui Medical University treated between January 2006 and December 2013. Sokal, EUTOS, and Hasford scores were compared with 3-month and 12-month CCyR, EFS, and PFS.
  
  
  RESULTS
  Kaplan-Meier analyses revealed that 3-month and 12-month CCyR and PFS were lower in patients with high EUTOS scores, and intermediate or high Sokal and Hasford scores (all P<0.05). Furthermore, EFS was lower in patients with intermediate or high Sokal and Hasford scores (both P<0.05). Hasford score (hazard ratio =2.608, 95% confidence interval: 1.473-4.617, P=0.001) was independently associated with 3-month CCyR.
  
  
  CONCLUSIONS
  Although all three scoring systems were associated with EFS, PFS, and 3-month and 12-month CCyR in the Kaplan-Meier analyses (except EFS with EUTOS), only the Hasford score was independently associated with 3m-CCyR, while EUTOS score and Sokal score were not independently associated with any of these outcomes.
authors.affiliation: Department of Hematology, The Third Affiliated Hospital of Anhui Medical University, Hefei, People's Republic of China ; Department of Hematology, Hefei Binhu Hospital, Hefei, People's Republic of China.
authors.forename: Leiming
authors.initials: L
authors.lastname: Xia
authors.affiliation: Department of Hematology, The Fourth Affiliated Hospital of Anhui Medical University, Hefei, People's Republic of China.
authors.forename: Wei
authors.initials: W
authors.lastname: Qian
authors.affiliation: Department of Hematology, The Fourth Affiliated Hospital of Anhui Medical University, Hefei, People's Republic of China ; Department of Hematology, The First Affiliated Hospital of Anhui Medical University, Hefei, People's Republic of China.
authors.forename: Mingzhen
authors.initials: M
authors.lastname: Yang
authors.affiliation: Department of Hematology, The First Affiliated Hospital of Anhui Medical University, Hefei, People's Republic of China.
authors.forename: Qingsheng
authors.initials: Q
authors.lastname: Li
authors.affiliation: Department of Hematology, The Second People's Hospital of Wuhu, Wuhu, People's Republic of China.
authors.forename: Fei
authors.initials: F
authors.lastname: Liu
authors.affiliation: Department of Hematology, The First Affiliated Hospital of Anhui Medical University, Hefei, People's Republic of China.
authors.forename: Yanyan
authors.initials: Y
authors.lastname: Xie
keywords: EUTOS; Hasford; Sokal; chronic-phase chronic myeloid leukemia; complete cytogenic response; prognosis